Steady-state mycophenolate mofetil pharmacokinetic parameters enable prediction of systemic lupus erythematosus clinical flares: An observational cohort study

Arthritis Research and Therapy

Volumn 12, Issue 6, 2010, Pages

  Djabarouti, Sarah ^a   Breilh, Dominique ^a   Duffau, Pierre ^b   Lazaro, Estibaliz ^b   Greib, Carine ^b   Caubet, Olivier ^b   Saux, Marie Claude ^a   Pellegrin, Jean Luc ^b   Viallard, Jean François ^b  

^a University Victor Segalen   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYCOPHENOLIC ACID BETA D GLUCURONIDE; PREDNISONE; UNCLASSIFIED DRUG; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; DISEASE ACTIVITY; FEMALE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; PARAMETER; SENSITIVITY AND SPECIFICITY; SYSTEMIC LUPUS ERYTHEMATOSUS; BLOOD; MASS SPECTROMETRY; MIDDLE AGED;

ADULT; AREA UNDER CURVE; COHORT STUDIES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MASS SPECTROMETRY; MIDDLE AGED; MYCOPHENOLIC ACID;

EID: 78650352152     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3202     Document Type: Article

References (13)

1. Nannini C, Crowson C, Matteson E, Moder KG. Mycophenolate mofetil is effective in reducing disease flares in systemic lupus erythematosus. Lupus 2009, 18:394-399. 10.1177/0961203308099242, 19318390.
2. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet 2007, 46:13-58. 10.2165/00003088-200746010-00002, 17201457.
3. Le Meur Y, Büchler M, Thierry A, Caillard S, Villemain F, Lavaud S, Etienne I, Westeel PF, Hurault de Ligny B, Rostaing L, Thervet E, Szelag JC, Rérolle JP, Rousseau A, Touchard G, Marquet P. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcome after renal transplantation. Am J Transplant 2007, 7:2496-2503. 10.1111/j.1600-6143.2007.01983.x, 17908276.
4. Barraclough KA, Staatz CE, Isbel NM, Johnson DW. Therapeutic monitoring of mycophenolate in transplantation: is it justified?. Curr Drug Metab 2009, 10:179-187. 10.2174/138920009787522205, 19275552.
5. Neumann I, Fuhrmann H, Fang IF, Jaeger A, Bayer P, Kovarik J. Association between mycophenolic acid 12-h trough levels and clinical endpoints in patients with autoimmune diseases on mycophenolate mofetil. Nephrol Dial Transplant 2008, 23:3514-3520. 10.1093/ndt/gfn360, 18586766.
6. Roland M, Barbet C, Paintaud G, Magdelaine-Beuzelin C, Diot E, Halimi JM, Lebranchu Y, Nivet H, Büchler M. Mycophenolate mofetil in patients with systemic lupus erythematosus: a prospective pharmacokinetic study. Lupus 2009, 18:441-447. 10.1177/0961203308098631, 19318398.
7. Djabarouti S, Duffau P, Xuereb F, Lazaro E, Greib C, Gordien JB, Caubet O, Saux MC, Viallard JF, Pellegrin JL, Breilh D. Measurement of total and unbound mycophenolic acid and its glucuronide by liquid chromatography coupled with mass spectrometry. Application to pharmacokinetic study of mycophenolate mofetil in patients with autoimmune diseases. Chromatographia 2009, 70:939-945.
8. Petri M, Genovese M, Engle E, Hochberg M. Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study. Arthritis Rheum 1991, 34:937-344. 10.1002/art.1780340802, 1859487.
9. Walz LeBlanc BA, Gladman DD, Urowitz MB. Serologically active clinically quiescent systemic lupus erythematosus-predictors of clinical flares. J Rheumatol 1994, 21:2239-2241.
10. Posalski J, Ishimori M, Wallace DJ, Weisman MH. Does mycophenolate mofetil prevent extra-renal flares in systemic lupus erythematosus? Results from an observational study of patients in a single practice treated for up to 5 years. Lupus 2009, 18:516-521. 10.1177/0961203308099471, 19395453.
11. Morissette P, Albert C, Busque S, St-Louis G, Vinet B. In vivo higher glucuronidation of mycophenolic acid in male than in female recipients of a cadaveric kidney allograft and under immunosuppressive therapy with mycophenolate mofetil. Ther Drug Monit 2001, 23:520-525. 10.1097/00007691-200110000-00004, 11591897.
12. Zahr N, Arnaud L, Marquet P, Haroche J, Costedoat-Chalumeau N, Hulot JS, Funck-Brentano C, Piette JC, Amoura Z. Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil. Arthritis Rheum 2010, 62:2047-2054.
13. Bernard O, Guillemette C. The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants. Drug Metab Dispos 2004, 32:775-778. 10.1124/dmd.32.8.775, 15258099.